Heron Therapeutics (HRTX) vs Nomad Power Solutions (NMAD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nomad Power Solutions (NMAD) has outperformed Heron Therapeutics (HRTX) over the past year, losing 14.5% versus a loss of 70.9%. Over five years, NMAD leads with a -77.3% price change compared with -96.4% for HRTX. Nomad Power Solutions is the larger company by market cap ($68.8 million vs $68.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | NMAD |
|---|---|---|
| Share price | $0.3582 | $4.27 |
| Market cap | $68.01M | $68.75M |
| 1-day change | -6.79% | +0.47% |
| YTD return | -70.44% | +8.14% |
| 1-year return | -70.89% | -14.49% |
| 5-year return | -96.37% | -77.27% |
| EPS (TTM) | $-0.18 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.58 | $8.38 |
| 52-week low | $0.26 | $2.36 |
| Distance from 52-week high | -77.33% | -49.05% |
| Average volume | 2.58M | 277.61K |
| Shares outstanding | 189.85M | 16.10M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NMAD has outperformed HRTX by 56.4 percentage points over the past year.
HRTX vs NMAD FAQ
Which is bigger, Heron Therapeutics or Nomad Power Solutions?
Nomad Power Solutions (NMAD) is larger, with a market capitalization of $68.75M compared with $68.01M for Heron Therapeutics (HRTX).
Which stock has performed better over the past year, HRTX or NMAD?
NMAD returned -14.49% over the past 12 months, compared with -70.89% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and Nomad Power Solutions in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.